Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XBJHU
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
LY-3076226
|
|||||
| Synonyms |
Anti-FGFR3 Ab IMC-D11; LY3076226; LY 3076226
Click to Show/Hide
|
|||||
| Organization |
Eli Lilly & Co.
|
|||||
| Drug Status |
Terminated in phase 1
|
|||||
| Indication |
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Terminated in phase 1
|
|||||
| Structure |
|
|||||
| Antibody Name |
IMC-D11
|
Antibody Info | ||||
| Antigen Name |
Fibroblast growth factor receptor 3 (FGFR3)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM4
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
| Combination Type |
Ravtansine
|
|||||
| Puchem SID | ||||||
| ChEBI ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.